206 related articles for article (PubMed ID: 34510321)
1. Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
Rubio-Tomás T
Mol Biol Rep; 2021 Nov; 48(11):7499-7508. PubMed ID: 34510321
[TBL] [Abstract][Full Text] [Related]
2. Functions of SMYD proteins in biological processes: What do we know? An updated review.
Rueda-Robles A; Audano M; Álvarez-Mercado AI; Rubio-Tomás T
Arch Biochem Biophys; 2021 Nov; 712():109040. PubMed ID: 34555372
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Yi X; Jiang XJ; Fang ZM
Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
[TBL] [Abstract][Full Text] [Related]
4. Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases.
Padilla A; Manganaro JF; Huesgen L; Roess DA; Brown MA; Crans DC
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838987
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
[TBL] [Abstract][Full Text] [Related]
6. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
[TBL] [Abstract][Full Text] [Related]
7. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
Xu S; Zhong C; Zhang T; Ding J
J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
[TBL] [Abstract][Full Text] [Related]
9. The SMYD family proteins in immunology: An update of their obvious and non-obvious relations with the immune system.
Rubio-Tomás T
Heliyon; 2021 Jun; 7(6):e07387. PubMed ID: 34235289
[TBL] [Abstract][Full Text] [Related]
10. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
11. Conformational Dynamics of Lysine Methyltransferase Smyd2. Insights into the Different Substrate Crevice Characteristics of Smyd2 and Smyd3.
Chandramouli B; Chillemi G
J Chem Inf Model; 2016 Dec; 56(12):2467-2475. PubMed ID: 27959541
[TBL] [Abstract][Full Text] [Related]
12. Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.
Taylor AP; Swewczyk M; Kennedy S; Trush VV; Wu H; Zeng H; Dong A; Ferreira de Freitas R; Tatlock J; Kumpf RA; Wythes M; Casimiro-Garcia A; Denny RA; Parikh MD; Li F; Barsyte-Lovejoy D; Schapira M; Vedadi M; Brown PJ; Arrowsmith CH; Owen DR
J Med Chem; 2019 Sep; 62(17):7669-7683. PubMed ID: 31415173
[TBL] [Abstract][Full Text] [Related]
13. Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.
Oliveira-Santos W; Rabello DA; Lucena-Araujo AR; de Oliveira FM; Rego EM; Pittella Silva F; Saldanha-Araujo F
Tumour Biol; 2016 Jul; 37(7):9473-81. PubMed ID: 26790435
[TBL] [Abstract][Full Text] [Related]
14. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2.
Abu-Farha M; Lanouette S; Elisma F; Tremblay V; Butson J; Figeys D; Couture JF
J Mol Cell Biol; 2011 Oct; 3(5):301-8. PubMed ID: 22028380
[TBL] [Abstract][Full Text] [Related]
15. Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.
Chandra P; Dixit R; Pratap A; Mishra S; Mishra R; Shukla VK
Indian J Surg Oncol; 2021 Apr; 12(Suppl 1):111-117. PubMed ID: 33994736
[TBL] [Abstract][Full Text] [Related]
16. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
[TBL] [Abstract][Full Text] [Related]
17. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
Liu C; Fang X; Ge Z; Jalink M; Kyo S; Björkholm M; Gruber A; Sjöberg J; Xu D
Cancer Res; 2007 Mar; 67(6):2626-31. PubMed ID: 17363582
[TBL] [Abstract][Full Text] [Related]
18. Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation.
Su H; Meng C; Xu J; Su Z; Xiao C; Yang D
Cell Death Dis; 2022 Oct; 13(10):890. PubMed ID: 36270984
[TBL] [Abstract][Full Text] [Related]
19. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.
Zhu CL; Huang Q
Dig Dis Sci; 2020 Feb; 65(2):489-499. PubMed ID: 31441002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
